UCSF has joined a growing network devoted to combating primary hyperoxaluria. As part of this initiative, patients can now ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $406.0, a high estimate of $550.00, and a low estimate of $333.00. This current average reflects ...

Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11. ・ALNY has a 100% technical ...

We can see that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) does use debt in its business. But is this debt a concern to shareholders? Debt assists a business until the business has trouble paying it ...

Investors might want to bet on Alnylam Pharmaceuticals (ALNY), as earnings estimates for this company have been showing solid ...

Alnylam stock jumps after Q2 earnings beat and higher 2025 guidance, led by Amvuttra's rapid uptake and strong growth across ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

The better-than-expected launch of a rare heart disease drug pushed Alnylam (Nasdaq: ALNY) past the $50 billion market ...

In the last 3 months, 9 analysts have offered 12-month price targets for Alnylam Pharmaceuticals. The company has an average price target of $209.67 with a high of $273.00 and a low of $108.00.

Alnylam Pharmaceuticals has seen its stock rise by 17% this year. The stock now trades at over 33x projected 2020 revenues, despite the fact that the company is likely to post another loss this year.

Alnylam Pharmaceuticals (NASDAQ: ALNY) last week reported the first sales for its hereditary transthyretin-mediated (hATTR) amyloidosis drug Onpattro, which was approved by the Food and Drug ...